MA31336B1 - Inhibiteurs de pi3k alpha a base de pyridopyrimidinone - Google Patents

Inhibiteurs de pi3k alpha a base de pyridopyrimidinone

Info

Publication number
MA31336B1
MA31336B1 MA32314A MA32314A MA31336B1 MA 31336 B1 MA31336 B1 MA 31336B1 MA 32314 A MA32314 A MA 32314A MA 32314 A MA32314 A MA 32314A MA 31336 B1 MA31336 B1 MA 31336B1
Authority
MA
Morocco
Prior art keywords
pyridoperimidineone
pi3k
depend
alpha inhibitors
compounds
Prior art date
Application number
MA32314A
Other languages
Arabic (ar)
English (en)
Inventor
Chris A Buhr
Longcheng Wang
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA31336B1 publication Critical patent/MA31336B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

L'invention concerne des composés de formule (i). Les composés de l'invention inhibent, régulent, et/ou modulent l'activité de la kinase p13k et sont utiles dans le traitement de maladies hyperprolifératives, comme le cancer.
MA32314A 2007-04-11 2009-10-30 Inhibiteurs de pi3k alpha a base de pyridopyrimidinone MA31336B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91116007P 2007-04-11 2007-04-11
PCT/US2008/004807 WO2008127712A1 (fr) 2007-04-11 2008-04-11 Composés pyrido [2, 3-d] pyrimidin-7-one utilisés en tant qu'inhibiteurs de pi3k-alpha pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MA31336B1 true MA31336B1 (fr) 2010-04-01

Family

ID=39642739

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32314A MA31336B1 (fr) 2007-04-11 2009-10-30 Inhibiteurs de pi3k alpha a base de pyridopyrimidinone

Country Status (26)

Country Link
US (2) US20100209340A1 (fr)
EP (1) EP2142544B8 (fr)
JP (1) JP2010523681A (fr)
KR (1) KR20090130104A (fr)
CN (1) CN101711249A (fr)
AU (1) AU2008239596B2 (fr)
BR (1) BRPI0810175A2 (fr)
CA (1) CA2683820A1 (fr)
CO (1) CO6241119A2 (fr)
CR (1) CR11098A (fr)
DO (1) DOP2009000242A (fr)
EA (1) EA018964B1 (fr)
EC (1) ECSP099722A (fr)
ES (1) ES2425068T3 (fr)
HK (1) HK1139941A1 (fr)
IL (1) IL201209A0 (fr)
MA (1) MA31336B1 (fr)
MX (1) MX2009010815A (fr)
MY (1) MY150747A (fr)
NI (1) NI200900183A (fr)
NZ (1) NZ579945A (fr)
SV (1) SV2009003389A (fr)
TN (1) TN2009000389A1 (fr)
UA (1) UA101315C2 (fr)
WO (1) WO2008127712A1 (fr)
ZA (1) ZA200906648B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065703A1 (fr) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyridopyrimidinones, dihydropyrimidopyrimidinones et pteridinones utiles en tant qu'inhibiteurs des kinases raf
BRPI0617159B8 (pt) * 2005-10-07 2021-05-25 Exelixis Inc compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
JP5270353B2 (ja) * 2005-10-07 2013-08-21 エクセリクシス， インク． ホスファチジルイノシトール３−キナーゼインヒビターとその使用方法
AU2007284562B2 (en) 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
WO2008032162A1 (fr) 2006-09-15 2008-03-20 Pfizer Products Inc. Composés de pyrido (2, 3-d) pyrimidin0ne et leur utilisation en tant qu'inhibiteurs de pi3
UA100979C2 (ru) 2007-04-10 2013-02-25 Экселиксис, Инк. Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака
EP2142543B8 (fr) * 2007-04-11 2013-07-03 Exelixis, Inc. Composés pyrido [2, 3-d]pyrimidin-7-one utilisés en tant qu'inhibiteurs de pi3k-alpha pour le traitement du cancer
PA8843901A1 (es) * 2008-09-30 2010-05-26 INHIBIDORES DE PIRIMIDINONA DE PI3K( ALFA) Y m TOR
US20120040950A1 (en) * 2009-12-22 2012-02-16 Vertex Pharmaceuticals Incorporated Isoindolinone inhibitors of phosphatidylinositol 3-kinase
TW201139436A (en) 2010-02-09 2011-11-16 Exelixis Inc Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
WO2012037204A1 (fr) 2010-09-14 2012-03-22 Exelixis, Inc. Inhibiteurs de pi3k-δ et leurs procédés d'utilisation et fabrication
WO2013056067A1 (fr) * 2011-10-13 2013-04-18 Exelixis, Inc. Composés pour une utilisation dans le traitement de carcinome des cellules basales
CN107375289A (zh) 2011-11-01 2017-11-24 埃克塞利希斯股份有限公司 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3‑激酶抑制剂的化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2937284A (en) * 1958-05-01 1960-05-17 Burroughs Wellcome Co 2, 4-diamino-5, 6-dialkylpyrido (2, 3-d) pyrimidines and method
IL117923A (en) * 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US7019002B2 (en) * 2001-12-11 2006-03-28 Pharmacia & Upjohn, S.P.A. Pyridopyrimidinones derivatives as telomerase inhibitors
US20080255162A1 (en) * 2004-05-04 2008-10-16 Warner-Lambert Company Llc Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents
CA2624965A1 (fr) * 2005-10-07 2007-04-19 Exelixis, Inc. Inhibiteurs pyridopyrimidinone de pi3ka
BRPI0617159B8 (pt) * 2005-10-07 2021-05-25 Exelixis Inc compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
AU2007284562B2 (en) * 2006-08-16 2013-05-02 Exelixis, Inc. Using PI3K and MEK modulators in treatments of cancer
WO2008032162A1 (fr) * 2006-09-15 2008-03-20 Pfizer Products Inc. Composés de pyrido (2, 3-d) pyrimidin0ne et leur utilisation en tant qu'inhibiteurs de pi3

Also Published As

Publication number Publication date
EA200970936A1 (ru) 2010-02-26
IL201209A0 (en) 2010-05-31
CA2683820A1 (fr) 2008-10-23
US20100209340A1 (en) 2010-08-19
UA101315C2 (ru) 2013-03-25
HK1139941A1 (en) 2010-09-30
AU2008239596B2 (en) 2013-08-15
MX2009010815A (es) 2009-10-29
US20130343988A1 (en) 2013-12-26
CO6241119A2 (es) 2011-01-20
JP2010523681A (ja) 2010-07-15
DOP2009000242A (es) 2010-04-30
EP2142544B8 (fr) 2013-07-03
ES2425068T3 (es) 2013-10-11
AU2008239596A1 (en) 2008-10-23
EP2142544B1 (fr) 2013-05-22
TN2009000389A1 (en) 2010-12-31
NZ579945A (en) 2012-05-25
NI200900183A (es) 2010-10-05
CR11098A (es) 2010-01-27
ECSP099722A (es) 2009-12-28
CN101711249A (zh) 2010-05-19
EP2142544A1 (fr) 2010-01-13
WO2008127712A1 (fr) 2008-10-23
EA018964B1 (ru) 2013-12-30
KR20090130104A (ko) 2009-12-17
SV2009003389A (es) 2010-04-27
MY150747A (en) 2014-02-28
ZA200906648B (en) 2010-04-28
BRPI0810175A2 (pt) 2014-12-30

Similar Documents

Publication Publication Date Title
MA31336B1 (fr) Inhibiteurs de pi3k alpha a base de pyridopyrimidinone
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
MA31167B1 (fr) Inhibiteurs de l'activite de akt
HK1135103A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MX2009012066A (es) Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
TW200634012A (en) 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents
ATE525375T1 (de) Hemmer von janus-kinasen und/oder 3- phosphoinositid-abhängiger protein-kinase 1
MA27933A1 (fr) Inhibiteurs de l'activite de akt
BRPI0510177A (pt) heterociclos monocìclicos como inibidores de cinase
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
TW200714604A (en) Substituted heterocycles and the uses thereof
EA200800664A1 (ru) Производные пирролопиримидина в качестве ингибиторов syk
MX2009006195A (es) Compuestos basados en 4-fenil-6-(2,2,2-trifluoro-1-feniletoxi)piri midina y metodos de su uso.
EA200801362A1 (ru) Пиримидинил бензотиофеновые соединения
EA200870218A1 (ru) Замещенные имидазольные производные, композиции и способы применения в качестве ингибиторов ртразы
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
TN2009000142A1 (en) Bicyclic triazoles as protein kinase modulators
EA200800014A1 (ru) Аминохинолиновые и аминохиназолиновые модуляторы киназы
MX2009004623A (es) Imidazopiridazinas como inhibidores de la lipido cinasa pi3k.
MA33155B1 (fr) Composes organiques et leurs utilisations
EA200971141A1 (ru) Соединения, активирующие теломеразу, и способы их применения
EA201291055A1 (ru) Ингибиторы протеинтирозинкиназной активности и их применение для лечения глазных заболеваний
EA201170344A1 (ru) Азаиндольные ингибиторы iap